SCHEMBL6504830

SCHEMBL6504830

CCN(CCNC(=O)Cc1ccc(OCc2ccccc2)cc1)Cc1cccc(Oc2ccccc2)c1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BCHE P06276 4/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
FFAR1 O14842 4/20 0.48
EPHX2 P34913 3/20 0.48
FFAR4 Q5NUL3 1/20 0.48
TSHR P16473 1/20 0.47
HSD17B10 Q99714 1/20 0.47
KDM4E B2RXH2 1/20 0.47
ALDH1A1 P00352 1/20 0.47
GAA P10253 1/20 0.47
MAPT P10636 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
LTA4H P09960 2/20 0.46
ALOX5 P09917 2/20 0.46
PTGES O14684 1/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
CHRM4 P08173 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6499395 0.94 BCHE (0.56) BCHEL3MBTL1FFAR1EPHX2FFAR4
SCHEMBL6503729 0.88 EPHX2 (0.58) BCHEEPHX2TSHRHSD17B10KDM4E
SCHEMBL6508701 0.86 KDM4E (0.50) BCHETSHRHSD17B10KDM4EALDH1A1
SCHEMBL6499688 0.86 CYP1A2 (0.56) BCHEFFAR1TSHRHSD17B10KDM4E
SCHEMBL6498720 0.84 BCHE (0.59) BCHEL3MBTL1TSHRHSD17B10SMN1; SMN2
SCHEMBL6505559 0.83 EPHX2 (0.56) BCHEEPHX2TSHRHSD17B10ALDH1A1
SCHEMBL6500610 0.82 GAA (0.59) BCHEFFAR1FFAR4TSHRHSD17B10
SCHEMBL6507435 0.82 RAB9A (0.49) BCHETSHRHSD17B10KDM4EALDH1A1
SCHEMBL6507792 0.80 MTNR1A (0.51) TSHRHSD17B10KDM4EGAAMEN1
SCHEMBL6506029 0.80 LMNA (0.55) BCHETSHRHSD17B10GAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143372-A1 Compounds, pharmaceutical compositions and methods of use therefor MILLENNIUM PHARMACEUTICALS, INC. 2005-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143372-A1 Compounds, pharmaceutical compositions and methods of use therefor CCR8, CCL11, CCR5 BCHE 945/4885L3MBTL1 4677/4885FFAR1 75/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.